A federal advisory panel voted to increase access to a popular peptide. Here's what that means.

A federal advisory panel has voted to increase access to a popular peptide. Here's what that means.

A federal advisory committee has recommended making BPC-157, a peptide popular in online wellness and fitness circles, available again through licensed compounding pharmacies.

The FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the 503A Bulks List, the set of substances that compounding pharmacies may prepare for patients who have a prescription, Ivim Health reports. Compounded medications are mixed by a specialized pharmacist and formulated for an individual patient. This is typically done when FDA-approved drugs don’t work, often because of allergies, delivery methods or dosage strengths.

The recommendation is not binding; the FDA usually follows its advisory panels but is not required to. A place on the list is also not the same as FDA approval of BPC-157 as a drug.

One detail is easy to miss.

The committee evaluated BPC-157 for ulcerative colitis, a form of inflammatory bowel disease, not the injury-recovery and training uses that drive most of its online popularity. However, if the FDA follows the July 23 favorable vote, the peptide can be prescribed and compounded for other uses.

What do we know about BPC-157?

BPC-157 is a synthetic peptide, a short chain of amino acids based on a protein found in human gastric juice. It’s sometimes referred to online as a “wolverine peptide” because much of the interest centers on tissue repair. Many of BPC-157’s loudest supporters and users claim the drug reduced joint pain, sped up injury recovery, and improved their gut health.

However, evidence on its efficacy is thin. Most of the research is new and done on animals. Clinical human data is extremely limited. A review published last year found that across 544 articles published about BPC-157 between 1993 and 2024, only 36 were original work. Of those, just one study was done on humans, with only 12 patients.

More from this section

+3

Pros and cons of GLP-1 shots over pills? Doc weighs in

A federal advisory panel voted to increase access to a popular peptide. Here's what that means.

Supporters point to a large real-world usage record with few reported problems. Skeptics counter that those figures come from voluntary reporting rather than controlled trials, and that questions remain about immunogenicity, whether the body mounts an immune response to the peptide. Some clinicians have also raised concerns that BPC-157’s influence on growth-related pathways could present a risk of tumor growth in cancerous cells.

What does this mean for patients?

For patients, the practical implications are narrow. Even if the FDA adopts the recommendation, BPC-157 would remain prescription-only, available through a licensed pharmacy and requiring a clinician to weigh a patient’s history against still-limited evidence. It would not become a product to buy and use on one’s own.

The FDA’s vote follows a 2023 reclassification that pulled BPC-157 out of the reach of licensed compounding pharmacies. But demand did not disappear three years ago. Physicians who testified at the hearing described patients continuing to use the peptide, now sourced from unregulated online sellers rather than pharmacies.

One report found peptides ordered from this digital “gray market,” had inconsistent purity levels, often nowhere near what was advertised, and even contained lead.

“They come for a visit and hold up a vial with no label, no dose, no ingredient list, something they ordered based on a video they saw on their phone,” said Dr. Jessica Duncan, an obesity medicine physician and chief medical officer at the telehealth practice Ivim Health, who testified before the panel. “They don’t know what they’ve actually been taking, or how much.”

Supporters argue that allowing BPC-157 and similar peptides back on the compounding list would pave the way for safer use.

What the vote may do is reopen a supervised path to a compound many people are already obtaining through unregulated channels. What it does not do is settle how well BPC-157 works, or for whom. For anyone considering it, the safest first step is the same as before the vote: a conversation with a clinician rather than a purchase of unknown origin.

The panel also voted to approve five other peptides: KPV, TB-500, MOTS-c, Epitalion, and Semax. Only one peptide put in front of the panel, Emideltide, was voted no.

This story was produced by Ivim Health and reviewed and distributed by Stacker.